FibroGen Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos de FibroGen disminuyan a un ritmo anual de 1.4%, mientras que se prevé que sus beneficios anuales crezcan a un ritmo de 71.4% por año. Se espera que el BPA crezca en un 74.5% al año.

Información clave

71.4%

Tasa de crecimiento de los beneficios

74.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	28.4%
Tasa de crecimiento de los ingresos	-1.4%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

Oct 29

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

Aug 19

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

Jul 04

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

Mar 22

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

Feb 05

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Dec 22

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Nov 24

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Apr 18

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Feb 13

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Nov 12

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Oct 09

FibroGen completes patient enrollment for Roxadustat to treat anemia in patients

Aug 26

FibroGen Q2 2022 Earnings Preview

Aug 05

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Jul 06

Is FibroGen (NASDAQ:FGEN) Using Debt Sensibly?

Mar 31

Time To Worry? Analysts Are Downgrading Their FibroGen, Inc. (NASDAQ:FGEN) Outlook

Mar 05

Is FibroGen (NASDAQ:FGEN) Using Debt In A Risky Way?

Dec 08

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:FGEN - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	177	-9	N/A	N/A	2
12/31/2025	152	-44	N/A	N/A	2
12/31/2024	173	-89	N/A	N/A	2
9/30/2024	180	-122	-126	-126	N/A
6/30/2024	174	-168	-203	-202	N/A
3/31/2024	167	-240	-275	-273	N/A
12/31/2023	148	-284	-318	-315	N/A
9/30/2023	155	-294	-352	-349	N/A
6/30/2023	131	-322	-319	-317	N/A
3/31/2023	116	-307	-242	-239	N/A
12/31/2022	141	-294	-185	-146	N/A
9/30/2022	123	-362	-188	-148	N/A
6/30/2022	263	-220	-118	-52	N/A
3/31/2022	258	-281	-112	-46	N/A
12/31/2021	235	-290	-112	-82	N/A
9/30/2021	284	-215	-66	-34	N/A
6/30/2021	172	-231	-85	-80	N/A
3/31/2021	190	-183	92	96	N/A
12/31/2020	176	-189	78	82	N/A
9/30/2020	119	-229	40	44	N/A
6/30/2020	108	-311	13	18	N/A
3/31/2020	257	-110	-166	-161	N/A
12/31/2019	257	-77	-84	-79	N/A
9/30/2019	357	42	-58	-51	N/A
6/30/2019	353	49	-22	-15	N/A
3/31/2019	205	-90	-28	-22	N/A
12/31/2018	213	-86	-84	-76	N/A
9/30/2018	136	-141	-68	-60	N/A
6/30/2018	147	-123	N/A	-87	N/A
3/31/2018	133	-132	N/A	-71	N/A
12/31/2017	131	-121	N/A	-67	N/A
9/30/2017	132	-121	N/A	-84	N/A
6/30/2017	122	-121	N/A	-67	N/A
3/31/2017	181	-64	N/A	-3	N/A
12/31/2016	183	-58	N/A	7	N/A
9/30/2016	172	-79	N/A	-14	N/A
6/30/2016	162	-100	N/A	-50	N/A
3/31/2016	193	-67	N/A	6	N/A
12/31/2015	181	-86	N/A	-19	N/A
9/30/2015	172	-85	N/A	-3	N/A
6/30/2015	167	-79	N/A	4	N/A
3/31/2015	136	-98	N/A	-4	N/A
12/31/2014	138	-60	N/A	22	N/A
9/30/2014	134	-24	N/A	24	N/A
6/30/2014	191	43	N/A	128	N/A
3/31/2014	117	-5	N/A	30	N/A
12/31/2013	102	-15	N/A	26	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que FGEN siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que FGEN siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que FGEN siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de FGEN disminuyan en los próximos 3 años (-1.4% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de FGEN disminuyan en los próximos 3 años (-1.4% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de FGEN se prevé que sea elevada dentro de 3 años.

FibroGen Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus estimates of losses per share improve by 17%

Price target decreased by 17% to US$10.38

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Consensus EPS estimates fall by 20%, revenue upgraded

Price target increased by 16% to US$24.83

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 26% Pounding

FibroGen Receives Nasdaq Notification of Non-Compliance with Minimum Bid Price Requirement

The Market Doesn't Like What It Sees From FibroGen, Inc.'s (NASDAQ:FGEN) Revenues Yet As Shares Tumble 65%

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies

Consensus estimates of losses per share improve by 17%

FibroGen, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding

FibroGen, Inc.(NasdaqGS:FGEN) dropped from Russell 3000 Index

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen, Inc. Announces FDA Clearance of Investigational New Drug Application for FG-3165, A Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at the 2024 American Society of Clinical Oncology Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Benign Growth For FibroGen, Inc. (NASDAQ:FGEN) Underpins Stock's 28% Plummet

FibroGen, Inc. to Report Q1, 2024 Results on May 06, 2024

FibroGen, Inc. to Present Clinical Data from Dose Escalation Phase 1B Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer at 2024 American Society of Clinical Oncology Annual Meeting

Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals Announce Settlement with FibroGen, Inc

Fibrogen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen, Inc.'s (NASDAQ:FGEN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too

CEO & Director recently bought US$95k worth of stock

FibroGen Appoints Deyaa Adib as Senior Vice President and Chief Medical Officer

Full year 2023 earnings: EPS and revenues miss analyst expectations

FibroGen, Inc. to Report Q4, 2023 Results on Feb 26, 2024

There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 148% Share Price Rise

New major risk - Financial position

FibroGen, Inc. Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen, Inc. (NASDAQ:FGEN) Held Back By Insufficient Growth Even After Shares Climb 42%

Now 25% undervalued after recent price drop

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

Now 30% undervalued after recent price drop

New minor risk - Financial position

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. Receives Non-Compliance Letter from Nasdaq Related to Minimum Bid Price

FibroGen, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 17% to US$10.38

FibroGen, Inc. Appoints Thane Wettig as Chief Executive Officer

Mark Eisner Resigns as Chief Medical Officer of Fibrogen, Inc., Effective September 8, 2023

Insufficient new directors

Fibrogen, Inc. Announces Topline Results from Lelantos-2, A Phase 3 Clinical Study of Pamrevlumab in Ambulatory Muscular Dystrophy

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Fibrogen, Inc. Announces Chief Executive Officer Changes

FibroGen, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Consensus revenue estimates decrease by 13%, EPS upgraded

Price target decreased by 25% to US$19.00

Now 81% undervalued after recent price drop

Insider notifies of intention to sell stock

FibroGen, Inc. Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy

FibroGen, Inc. Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Consensus EPS estimates fall by 20%, revenue upgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Revenues Not Telling The Story For FibroGen, Inc. (NASDAQ:FGEN)

Insider recently sold US$124k worth of stock

CEO & Director recently sold US$1.2m worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased by 16% to US$24.83

FibroGen, Inc. to Report Q4, 2022 Results on Feb 27, 2023

Health Check: How Prudently Does FibroGen (NASDAQ:FGEN) Use Debt?

Price target increased by 21% to US$21.33

Price target increased to US$17.60

Chief Financial Officer notifies of intention to sell stock

Now 20% undervalued

Price target increased to US$16.40

The FibroGen, Inc. (NASDAQ:FGEN) Analysts Have Been Trimming Their Sales Forecasts

Price target increased to US$16.40